Category

Pharmaceutical 3875 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Substantial growth expected in type 2 diabetes treatment market

januvia - sitagliptin

The global market for type 2 diabetes treatments is expected to increase in value over the next few years from a value of $23.5 billion in 2014 to an estimated $39 billion by 2021, fueled by the increasing number of people developing the disease and the barrage of new brand-name diabetes treatments entering the market. The prediction was made by business intelligence provider GBI Research, which published the report Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2012 – Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth. The company said the increase will occur across the ... Read More

Bayer’s profits may suffer due to Xarelto lawsuits

xarelto

Bayer AG is enjoying better-than-expected profits in its second-quarter statements thanks in part to its blockbuster blood thinner Xarelto, whose sales surged 43 percent to 549 million euros – or about 604 million U.S. dollars – in the quarter, about 3 million euros – or 3.3 million dollars – over analysts’ average estimates. But the anticoagulant’s growing sales are expected to hit a snag. Xarelto is facing competition from Pfizer’s Eliquis as well as litigation alleging life threatening bleeding events. Xarelto is in a new class of blood thinners aimed at taking market share from long-used warfarin for the treatment and ... Read More

Woman claims Mirena IUD caused partial blindness

mirena IUD

A woman who filed a lawsuit against Bayer Healthcare Pharmaceuticals Inc., alleging the company’s Mirena IUD (intrauterine device) caused her to go partially blind will move forward after a Kentucky federal judge kept alive two contested claims with strict liability and negligent misrepresentation. The judge did trim an implied warranty claim, supporting Bayer’s argument that the plaintiff did not buy the device directly from the company. Kara Stanley’s lawsuit claims she had the Mirena IUD inserted by a doctor at a women’s health care facility in southern Indiana in May 2012. Seven months later, she began having severe headaches and ... Read More

Tens of thousands of statin side effects reported to government agencies

lipitor

Tens of thousands of statin side effects associated with the use of  the cholesterol-lowering drugs in the past two decades have been reported to the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK’s drug regulating body, according to a new study. Statins, such as the widely prescribed Lipitor, are among the most prescribed drugs in the United States, United Kingdom, and in several countries around the world. New guidelines in both the U.S. and U.K. have broadened the indication for the drugs in an effort to reduce heart attacks and strokes in patients with elevated cholesterol levels. But statin side effects are not ... Read More

Woman sues Eliquis makers over husband’s bleeding death

xarelto

A woman has filed a lawsuit against Pfizer and Bristol-Myers Squibb Co., claiming the drug companies failed to warn her and her husband that the blood thinner Eliquis could cause potentially fatal bleeding events. Deobrah Herschell claims that her husband, Donald, took Eliquis for three months to treat his irregular heart rhythm, but died from a major gastrointestinal hemorrhage caused by the drug. Her lawsuit alleges that the drug makers “chose incompetent and untrustworthy agents in China” to conduct clinical trials in order to win Food and Drug Administration (FDA) approval, but hid unfavorable data from those studies. Herschell also ... Read More

Compounding pharmacy advocacy groups fight FDA’s proposed guidance

Syringe

Companies and trade groups are putting the heat on the Food and Drug Administration (FDA) claiming the agency’s proposed restrictions on interstate shipments of compounded drugs are confusing and hard to gauge. The concerns were raised following the February publishing of the FDA’s “memorandum of understanding,” or MOU, which proposed policies for state oversight of compounding pharmacies that are not listed as FDA-regulated outsourcing facilities. The public had until July 20 to offer comments on the MOU. A compounding pharmacy is not allowed under the Federal Food, Drug & Cosmetic Act to ship more than 5 percent of its products across state ... Read More

Power morcellator lawsuits could produce large awards

morcellator

Manufacturers of controversial power morcellators used to perform hysterectomies and uterine fibroid removal may not face a large number of lawsuits alleging cancer spread caused by the devices, but the awards or settlements could be huge, plaintiffs attorneys say. Victims and their family members harmed by power morcellators tend to have major medical bills and most are in their peak earing years. Power morcellators are surgical tools fitted with a tube-like blade that shreds uterine fibroids or entire uteruses inside the uterine cavity and removes them through a small incision in the abdomen. The devices have been favored over open ... Read More

People with genetically high cholesterol at lower risk of type 2 diabetes

lipitor

Cholesterol-lowering statin drugs are prescribed to lower cholesterol levels in order to prevent heart attacks and strokes. But recent studies show that people who take these drugs are at an increased risk of developing type 2 diabetes, a condition that can lead to serious health problems including heart disease, kidney disease, cancer, dementia and blindness. Determining who should take statins can be a crapshoot considering the statin side effects. But a study published recently in JAMA offers reassurance to at least one segment of the population. It found that people who have a genetic form of high cholesterol are less ... Read More

Clinical trial to test new combination melanoma treatments

melanoma

The ECOG-ACRIN Cancer Research Group will soon be recruiting patients with melanoma at cancer centers nationwide to participate in a study comparing the sequencing of two groups of effective melanoma treatments. The research is led by Georgetown University Medical Center physician Michael B. Atkins. “After many years of research, we’ve ended up with exciting and effective new combination treatment regimens. Now we need to figure out how to sequence these treatment regimens in order to best extend the lives of our patients,” he said. The study involves a combination of the drugs dabrafenib and trametinib, which work by directly attacking ... Read More

Victoza being tested as a treatment for nonalcoholic fatty liver disease

Victoza

The type 2 diabetes drug Victoza can help resolve a type of nonalcoholic fatty liver disease in overweight patients, according to a new study presented at the 2015 International Liver Congress. The specific nonalcoholic fatty liver disease is called nonalcoholic steatohepatitis, or NASH. It is a common, often “silent” liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The major feature with NASH is fat in the liver, along with inflammation and damage. Most people are not aware they have a liver problem. However, it can become severe and lead to cirrhosis, ... Read More